Posted by Michael Wonder on 08 Jul 2021
Lysogene announces FDA fast track designation for LYS-GM101 gene therapy for the treatment of GM1 gangliosidosis
8 July 2021 - Lysogene today announced that the U.S. FDA has granted fast track designation to its LYS-GM101 program, which is being studied in the recently initiated global adaptative-design clinical trial for the treatment of GM1 gangliosidosis.
No treatment has been approved so far for this disease.
